ACXP

$0.00

(

+0.00%

) Quote details
Add to Watchlist Run Backtest
stock

Acurx Pharmaceuticals LLC

NASDAQ | ACXP

7.01

USD

+$0.00

(

+0.00%

)

At Close (As of Oct 21, 2025)

$11.05M

Market Cap

-

P/E Ratio

-10.57

EPS

$39.20

52 Week High

$3.80

52 Week Low

HEALTHCARE

Sector

ACXP Chart

Recent Chart
Price Action

ACXP Technicals

Tags:

ACXP Earnings

Yearly Income Statement (As of Dec 31, 2024)

Field Value (USD)
Gross Profit -
Total Revenue $0
Cost Of Revenue -
Costof Goods And Services Sold -
Operating Income -$14M
Selling General And Administrative $8.7B
Research And Development $5.4M
Operating Expenses $14M
Investment Income Net -
Net Interest Income -
Interest Income -
Interest Expense -
Non Interest Income -
Other Non Operating Income -
Depreciation -
Depreciation And Amortization -
Income Before Tax -$14M
Income Tax Expense -$14B
Interest And Debt Expense -
Net Income From Continuing Operations -$14M
Comprehensive Income Net Of Tax -
Ebit -$14M
Ebitda -$14M
Net Income -$14M

Revenue & Profitability

Earnings Performance

ACXP Financials

yearly Balance Sheet (As of Dec 31, 2024)

Field Value (USD)
Total Assets $3.9M
Total Current Assets $3.9M
Cash And Cash Equivalents At Carrying Value $3.7M
Cash And Short Term Investments $3.7M
Inventory -
Current Net Receivables $51K
Total Non Current Assets $3.9B
Property Plant Equipment -
Accumulated Depreciation Amortization Ppe -
Intangible Assets -
Intangible Assets Excluding Goodwill -
Goodwill -
Investments -
Long Term Investments -
Short Term Investments -
Other Current Assets $100K
Other Non Current Assets -
Total Liabilities $3.2M
Total Current Liabilities $3.2M
Current Accounts Payable -
Deferred Revenue -
Current Debt -
Short Term Debt -
Total Non Current Liabilities $0
Capital Lease Obligations -
Long Term Debt -
Current Long Term Debt -
Long Term Debt Noncurrent -
Short Long Term Debt Total -
Other Current Liabilities $3.2M
Other Non Current Liabilities -
Total Shareholder Equity $615K
Treasury Stock -
Retained Earnings -$67M
Common Stock $17K
Common Stock Shares Outstanding $852K

yearly Cash Flow (As of Dec 31, 2024)

Field Value (USD)
Operating Cashflow -$10M
Payments For Operating Activities -
Proceeds From Operating Activities -
Change In Operating Liabilities -
Change In Operating Assets -
Depreciation Depletion And Amortization -
Capital Expenditures $0
Change In Receivables -
Change In Inventory -
Profit Loss -
Cashflow From Investment -
Cashflow From Financing $6.6M
Proceeds From Repayments Of Short Term Debt -
Payments For Repurchase Of Common Stock -
Payments For Repurchase Of Equity -
Payments For Repurchase Of Preferred Stock -
Dividend Payout -
Dividend Payout Common Stock -
Dividend Payout Preferred Stock -
Proceeds From Issuance Of Common Stock -
Proceeds From Issuance Of Long Term Debt And Capital Securities Net -
Proceeds From Issuance Of Preferred Stock -
Proceeds From Repurchase Of Equity -
Proceeds From Sale Of Treasury Stock -
Change In Cash And Cash Equivalents -
Change In Exchange Rate -
Net Income -$14M

yearly Income Statement (As of Dec 31, 2024)

Field Value (USD)
Gross Profit -
Total Revenue $0
Cost Of Revenue -
Costof Goods And Services Sold -
Operating Income -$14M
Selling General And Administrative $8.7B
Research And Development $5.4M
Operating Expenses $14M
Investment Income Net -
Net Interest Income -
Interest Income -
Interest Expense -
Non Interest Income -
Other Non Operating Income -
Depreciation -
Depreciation And Amortization -
Income Before Tax -$14M
Income Tax Expense -$14B
Interest And Debt Expense -
Net Income From Continuing Operations -$14M
Comprehensive Income Net Of Tax -
Ebit -$14M
Ebitda -$14M
Net Income -$14M

ACXP News

ACXP Profile

Acurx Pharmaceuticals LLC Profile

Sector: HEALTHCARE

Industry: BIOTECHNOLOGY

Acurx Pharmaceuticals, LLC (ACXP) is a clinical-stage biopharmaceutical company headquartered in Staten Island, New York, dedicated to developing innovative antibiotics for bacterial infections and addressing significant unmet medical needs. The company is focused on its lead product candidates that specifically target multi-drug resistant bacteria, a growing concern in global health. By leveraging advanced scientific approaches, Acurx aims to enhance the efficacy and safety of its therapeutics, thereby positioning itself as a pivotal player in the battle against antibiotic resistance and contributing to improved patient outcomes in the field of infectious diseases.

BYND
+146.25%
$3.62
VHAI
0.00%
$0.00
YDKG
+27.99%
$0.05
YYAI
-19.18%
$0.08
F
+4.75%
$12.56
VSEE
+93.56%
$0.94
CGBS
-39.47%
$0.03
NERV
+140.97%
$6.41
RANI
+26.66%
$2.85
NVDA
-0.81%
$181.16
GDXD
+28.69%
$0.86
AIRE
+61.36%
$0.72
BURU
-14.84%
$0.28
BITF
-9.83%
$4.49
PLUG
-8.23%
$3.12
ADAP
-17.62%
$0.04
T
-0.19%
$26.05
RGTI
-7.64%
$40.00
HPE
+1.74%
$23.27
CAN
-4.87%
$1.95
DNN
-7.16%
$2.72
BTG
-9.12%
$5.18
INTC
+0.05%
$38.11
WBD
+10.97%
$20.32
BOF
+33.65%
$2.80
JOBY
-7.63%
$16.10
DVLT
+4.54%
$2.52
CLF
-17.24%
$13.39
AXDX
-61.36%
$0.03
IBIO
+24.30%
$1.11
GSIT
-16.26%
$10.86
RIG
+0.60%
$3.31
TLRY
-5.73%
$1.48
NVTS
-12.10%
$15.03
RXRX
-8.53%
$6.11
ETHD
-0.80%
$3.72
SOFI
+0.24%
$28.75
ABEV
-2.20%
$2.22
TSLA
-1.07%
$442.60
RF
+1.24%
$24.36
AMZN
+2.56%
$222.03
EOSE
+8.59%
$16.30
GRAB
-1.23%
$5.60
GOOGL
-2.37%
$250.46
AMD
-1.05%
$238.03
AAPL
+0.20%
$262.77
LAES
-5.86%
$6.10
QUBT
-7.40%
$16.00
ACHR
-4.75%
$11.41
IONZ
+1.48%
$4.11
GM
+14.86%
$66.62
SOUN
-4.35%
$18.23
RR
+1.25%
$5.63
BTBT
-8.29%
$3.87
VALE
-1.14%
$11.27
BBD
-2.36%
$3.30
IREN
-6.79%
$55.19
PFE
+0.64%
$24.85
QBTS
-6.42%
$32.19
GPUS
-7.57%
$0.36
DCGO
+24.16%
$1.49
MARA
-3.18%
$20.07
HAL
+11.58%
$25.24
RMBL
+60.50%
$3.21
CJET
-20.45%
$0.08
AAL
+1.47%
$12.35
DFLI
-3.96%
$1.21
ADD
-25.47%
$0.05
CLSK
-7.99%
$18.77
NOK
-2.27%
$5.58
NIO
-3.68%
$6.80
SRM
+53.27%
$10.30
CIFR
-9.21%
$18.07
BMNR
-3.62%
$51.85
AMC
+4.33%
$2.89
KO
+4.06%
$71.22
SNAP
+1.55%
$7.85
PBR
-1.11%
$11.56
ONDS
-7.46%
$7.19
SMR
-13.20%
$38.36
VZ
-1.22%
$40.29
HBAN
+0.63%
$15.94
HIMS
-3.89%
$49.36
CUTR
-10.19%
$0.09
WTO
+2.93%
$0.06
SMCI
-0.39%
$54.82
GGB
-1.17%
$3.37
EPWK
-8.71%
$0.07
WLGS
-5.57%
$0.04
PM
-3.83%
$152.00
RIVN
+0.91%
$13.20
GOOG
-2.20%
$251.34
PLTR
-0.04%
$181.51
BAC
-0.99%
$51.52
APLD
-9.35%
$32.54
RGTZ
+15.11%
$15.61
ETWO
0.00%
$3.30
BULL
-2.96%
$11.14
IONQ
-0.73%
$59.50
MSN
+59.31%
$0.76
BYND
+146.25%
$3.62
VHAI
0.00%
$0.00
YDKG
+27.99%
$0.05
YYAI
-19.18%
$0.08
F
+4.75%
$12.56
VSEE
+93.56%
$0.94
CGBS
-39.47%
$0.03
NERV
+140.97%
$6.41
RANI
+26.66%
$2.85
NVDA
-0.81%
$181.16
GDXD
+28.69%
$0.86
AIRE
+61.36%
$0.72
BURU
-14.84%
$0.28
BITF
-9.83%
$4.49
PLUG
-8.23%
$3.12
ADAP
-17.62%
$0.04
T
-0.19%
$26.05
RGTI
-7.64%
$40.00
HPE
+1.74%
$23.27
CAN
-4.87%
$1.95
DNN
-7.16%
$2.72
BTG
-9.12%
$5.18
INTC
+0.05%
$38.11
WBD
+10.97%
$20.32
BOF
+33.65%
$2.80
JOBY
-7.63%
$16.10
DVLT
+4.54%
$2.52
CLF
-17.24%
$13.39
AXDX
-61.36%
$0.03
IBIO
+24.30%
$1.11
GSIT
-16.26%
$10.86
RIG
+0.60%
$3.31
TLRY
-5.73%
$1.48
NVTS
-12.10%
$15.03
RXRX
-8.53%
$6.11
ETHD
-0.80%
$3.72
SOFI
+0.24%
$28.75
ABEV
-2.20%
$2.22
TSLA
-1.07%
$442.60
RF
+1.24%
$24.36
AMZN
+2.56%
$222.03
EOSE
+8.59%
$16.30
GRAB
-1.23%
$5.60
GOOGL
-2.37%
$250.46
AMD
-1.05%
$238.03
AAPL
+0.20%
$262.77
LAES
-5.86%
$6.10
QUBT
-7.40%
$16.00
ACHR
-4.75%
$11.41
IONZ
+1.48%
$4.11
GM
+14.86%
$66.62
SOUN
-4.35%
$18.23
RR
+1.25%
$5.63
BTBT
-8.29%
$3.87
VALE
-1.14%
$11.27
BBD
-2.36%
$3.30
IREN
-6.79%
$55.19
PFE
+0.64%
$24.85
QBTS
-6.42%
$32.19
GPUS
-7.57%
$0.36
DCGO
+24.16%
$1.49
MARA
-3.18%
$20.07
HAL
+11.58%
$25.24
RMBL
+60.50%
$3.21
CJET
-20.45%
$0.08
AAL
+1.47%
$12.35
DFLI
-3.96%
$1.21
ADD
-25.47%
$0.05
CLSK
-7.99%
$18.77
NOK
-2.27%
$5.58
NIO
-3.68%
$6.80
SRM
+53.27%
$10.30
CIFR
-9.21%
$18.07
BMNR
-3.62%
$51.85
AMC
+4.33%
$2.89
KO
+4.06%
$71.22
SNAP
+1.55%
$7.85
PBR
-1.11%
$11.56
ONDS
-7.46%
$7.19
SMR
-13.20%
$38.36
VZ
-1.22%
$40.29
HBAN
+0.63%
$15.94
HIMS
-3.89%
$49.36
CUTR
-10.19%
$0.09
WTO
+2.93%
$0.06
SMCI
-0.39%
$54.82
GGB
-1.17%
$3.37
EPWK
-8.71%
$0.07
WLGS
-5.57%
$0.04
PM
-3.83%
$152.00
RIVN
+0.91%
$13.20
GOOG
-2.20%
$251.34
PLTR
-0.04%
$181.51
BAC
-0.99%
$51.52
APLD
-9.35%
$32.54
RGTZ
+15.11%
$15.61
ETWO
0.00%
$3.30
BULL
-2.96%
$11.14
IONQ
-0.73%
$59.50
MSN
+59.31%
$0.76
2025 © AfterPullback LTD

Charts powered by TradingView

Market data may be delayed by 15 minutes or more and is provided by financial exchanges or third-party providers. AfterPullback does not verify or guarantee its accuracy and assumes no responsibility to do so. This website is not operated by a licensed attorney, accountant, or financial advisor. Nothing on this site constitutes financial advice or replaces consultation with a qualified professional who understands your specific circumstances. Always consult a licensed financial advisor before making investment decisions.